Preview

Онкоурология

Расширенный поиск

РОЛЬ ХРОНИЧЕСКОГО ПРОСТАТИТА В ПАТОГЕНЕЗЕ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ

https://doi.org/10.17650/1726-9776-2011-7-2-12-17

Полный текст:

Аннотация

Представлен обзор современных взглядов на роль предшествующего воспаления в простате в развитии рака предстательной железы. Последовательные изменения клеточных структур характеризуются пролиферативной воспалительной атрофией и простатической интраэпителиальной неоплазией.

Об авторе

А. С. Переверзев
Харьковская медицинская академия последипломного образования, г. Харьков
Украина


Список литературы

1. De Mazzo A.M., Platz E.A., Sutchiffe A. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256–69.

2. Wagenlehner F.M., Elkahwaji J.E., Algaba F. et al. The role of inflammation and infection in the pathogenesis of prostate carcinoma. BJU Int 2007;100(4):733–7.

3. Аляев Ю.Г., Народицкий Б.С., Гудков А.В., Винаров А.З. и др. Возможна ли роль микоплазменной инфекции в патогенезе рака предстательной железы. В сб.: Материалы IV конгресса РООУ. М., 2009; с. 23.

4. Roberts R.O., Bergstralh E.J., Bass S.E. et al. Prostatitis as a risk factor for prostate cancer. Epidemiology 2004;15:93–9.

5. Bastian P.J., Nuhn P., Stadler T.C. et al. Prostatitis und Prostatakarzinom. Urologe 2010;49:636–8.

6. Daniels N.A., Ewing S.K., Zmuda J.M. Correlates and prevalence of prostatitis in a large community-based cohort of older men. Urology 2005; 66(5):964–70.

7. Dennis L.K., Lynch C.F., Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology 2002;60(1):78–83.

8. MacLennan G.T., Eisenberg R., Fleshman R.L. The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. J Urol 2006;176(3):1012–6.

9. Vinarov A.Z., Pshikhachev A.M., Varshavskij V.A., Stoilov S.V. Clinicallchronic prostatitis, and what is morphologically? 25 EAU Congress, 2010, abstr.368.

10. Wittschieber D., Schenkenberg S., Dietel M., Erbersdobler A. Die Bedeutung der chronischer Prostatitis fur die Pathogenese des Prostatakarzinoms. Urologe A 2010;49(8):947–51.

11. Maitland N.J., Collins A.T. Inflammation as the primary aetiological agent of human prostate cancer: a stem cell connection? J Cell Biochem 2008;105(4):931–9.

12. Vasto S., Carruba G., Candore G. et al. Inflammation and prostate cancer. Future Oncol 2008;4(5):637–45.

13. Klein E.A., Silverman R. Inflammation, infection, and prostate cancer. Curr Opin Urol 2008;18(3):315–9.

14. Palapattu G.S., Sutcliffe S., Bastian P.J. et al. Prostate carcinogenesis and inflammation: emerging insights. Cancerogenesis 2004;26:1170–81.

15. De Marzo A.M., Marchi V.L., Epstein J.I., Nelson W.G. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999;155(6):1985–92.

16. Taylor M.L., Mainous A.G., Wells B.J. Prostate cancer and sexually transmitted diseases: a meta-analysis. Fam Med 2005; 7(7):506–12.

17. Naber K., Lobel B., Weidner W. Further insights into endocrine disease the enigma of prostatitis. The International prostate health Council. Sant Malo, France, 2004;20–4.

18. Singh A., Purohit A., Ghilchik M.W. The regulation of aromatase activity in breast bibroblasts: the role of interleukin and prostaglandin E2. Endocr Relat Cancer 1999;6:139–47.

19. Shah R., Mucci N.R., Amin A. et al. Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander? Am J Pathol 2001;158(5):1767–73.

20. Haverkamp J., Charbonneau B., Ratliff T.L. Prostate inflammation and its potential impact on prostate cancer: a current review. J Cell Biochem 2008;103(5):1344–53.

21. Bastian P.J., Yegnasubramanian S., Palapattur G.S. Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. Eur Urol 2004;46:698–708.

22. Nakayama M., Bennett C.J., Hicks J.L. et al. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am J Pathol 2003;163(3):923–33.

23. Zheng S.L., Augustsson-Bälter K., Chang B. et al. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the Cаncer Prostate in Sweden Study. Cancer Res 2004; 15;64(8):2918–22.

24. Bardia A., Platz E.A., Yegnasubramanian S. et al. Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. Curr Opin Pharmacol 2009;9(4):419–26.

25. De Marzo A.M., Nelson W.G., Meeker A.K., Coffey D.S. Stem cell features of benign and malignant prostate epithelial cells. J Urol 1998;160:2381–92.

26. Bostwick D.G., Alexander E.E., Singh R. et al. Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer. Cancer 2000;89(1):123–34.

27. Kirby R.S. A randomized, doubleblind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. BJU Int 2003;91(1):41–4.


Для цитирования:


Переверзев А.С. РОЛЬ ХРОНИЧЕСКОГО ПРОСТАТИТА В ПАТОГЕНЕЗЕ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ. Онкоурология. 2011;7(2):12-17. https://doi.org/10.17650/1726-9776-2011-7-2-12-17

For citation:


Pere A.S. THE ROLE OF CHRONIC PROSTATITIS IN THE PATHOGENESIS OF PROSTATE CANCER. Cancer Urology. 2011;7(2):12-17. (In Russ.) https://doi.org/10.17650/1726-9776-2011-7-2-12-17

Просмотров: 434


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)
X